Invitrocue (Singapore Subsidiary)

Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalized oncology testing).

Invitrocue (Singapore Subsidiary) is privately held. The company is headquartered in Singapore

Alternatives.pe tracks Invitrocue (Singapore Subsidiary)'s financials, valuation trends, ownership structure and transaction activity over time.

You're on a preview of a profileGet a free trial to view it in full

Last Updated: 2026-07-21

You're on a preview of a profileGet a free trial to view it in full

Last Updated: 2026-07-21

Loading, please wait...

All information here may not be reproduced without explicit written permission from Alternatives.pe.

Glossary

Invitrocue (Singapore Subsidiary)

Invitrocue (Singapore Subsidiary)

Key Team Members

Documents

Related News

Employee Count

Key Team Members